Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

This study has been terminated.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00385593
First received: October 6, 2006
Last updated: November 30, 2010
Last verified: November 2010
  Purpose

This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept. The study will compare the Symbicort Single Inhaler Therapy concept with a conventional stepwise treatment regimen according to the investigator's judgement in patients who present with symptoms on inhaled glucocorticosteroids (GCS) treatment or who require and are already on treatment with a combination of inhaled and long-acting B2 agonists (LABA).


Condition Intervention Phase
Asthma, Bronchial
Drug: Symbicort (budesonide/formoterol) Turbuhaler
Drug: Conventional treatment
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 Micrograms, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-week, Randomised, Open-label, Parallel-group, Multicentre Study. Study SPAIN

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Time to First Severe Asthma Exacerbation [ Time Frame: Baseline up to 6 months ] [ Designated as safety issue: No ]
    Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral Glucocorticosteroids (GCS) treatment for at least 3 days.


Secondary Outcome Measures:
  • Total Number of Severe Exacerbations [ Time Frame: Baseline up to 6 months ] [ Designated as safety issue: No ]
    Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral (GCS) treatment for at least 3 days.

  • Mean Use of as Needed Medication [ Time Frame: Baseline up to 6 months ] [ Designated as safety issue: No ]
    Mean use of as needed medication during the treatment period

  • Use of Inhaled Steroids [ Time Frame: Baseline up to 6 months ] [ Designated as safety issue: No ]
    Mean micrograms/day of inhaled steroids (beclomethasone dipropionate equivalents)

  • Change in the Asthma Control Questionnaire(ACQ) Score [ Time Frame: Daily 14 days prior to each of visit 2-4 ] [ Designated as safety issue: No ]
    The ACQ is a 7-point scale with scores ranging from 0 (very well controlled) to 6 (very badly controlled)

  • Peak Expiratory Flow (PEF) [ Time Frame: 6 months (end of the study) ] [ Designated as safety issue: No ]
    Peak expiratory flow (PEF)


Enrollment: 654
Study Start Date: September 2006
Study Completion Date: October 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition (9).
  • Prescribed inhaled GCS at a dose of 400μg/day of budesonide (or equivalents)and within the approved label for the relevant drug during the last 3 months prior to Visit 1.
  • Either daily maintenance treatment with both inhaled GCS and LABA or daily treatment with inhaled GCS alone (i.e. without LABA)
  • A history of suboptimal asthma control the month prior to enrolment as judged by the investigator
  • Use of ≥3 inhalations of as needed medication for symptom relief during the last 7 days before enrolment

Exclusion Criteria:

  • Previous treatment with Symbicort Single Inhaler;
  • Use of any b-blocking agent, including eye-drops and oral GCS as maintenance treatment.
  • Known or suspected hypersensitivity to study therapy or excipients.
  • A history of smoking ≥ 10 pack years.
  • Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to or at Visit 1.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00385593

  Hide Study Locations
Locations
Spain
Research Site
A Coruna, Spain
Research Site
Alagon, Spain
Research Site
Alicante, Spain
Research Site
Almoradi, Spain
Research Site
Barcelona, Spain
Research Site
Burgos, Spain
Research Site
Cadiz, Spain
Research Site
Caravaca, Spain
Research Site
Cartagena, Spain
Research Site
Cordoba, Spain
Research Site
Coslada, Spain
Research Site
Dos Hermanas, Spain
Research Site
Elche, Spain
Research Site
Fuencarral, Spain
Research Site
Fuenlabrada, Spain
Research Site
Galdacano, Spain
Research Site
Gallur, Spain
Research Site
Gandia, Spain
Research Site
Getafe, Spain
Research Site
Gijon, Spain
Research Site
Granada, Spain
Research Site
Huelva, Spain
Research Site
Huesca, Spain
Research Site
Idiazabal, Spain
Research Site
Jaen, Spain
Research Site
Lugo, Spain
Research Site
Madrid, Spain
Research Site
Malaga, Spain
Research Site
Mataro, Spain
Research Site
Oviedo, Spain
Research Site
Pamplona, Spain
Research Site
Pinto, Spain
Research Site
Pozuelo de Alarcon, Spain
Research Site
Sagunto, Spain
Research Site
Salamanca, Spain
Research Site
San Juan, Spain
Research Site
San Sebastian, Spain
Research Site
Santander, Spain
Research Site
Santiago, Spain
Research Site
Santiago de Compostela, Spain
Research Site
Sevilla, Spain
Research Site
Terrassa, Spain
Research Site
Valdemoro, Spain
Research Site
Valencia, Spain
Research Site
Valladolid, Spain
Research Site
Vigo, Spain
Research Site
Viladecans, Spain
Research Site
Vilanova, Spain
Research Site
Villabona, Spain
Research Site
Villanueva de la Canada, Spain
Research Site
Vitoria, Spain
Research Site
Zaragoza, Spain
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Carlos Barcina, MD AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00385593     History of Changes
Other Study ID Numbers: D5890L00010, 2005-005974-64, SPAIN
Study First Received: October 6, 2006
Results First Received: October 14, 2009
Last Updated: November 30, 2010
Health Authority: Spain: Spanish Agency of Medicines

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Budesonide
Formoterol
Symbicort
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Anti-Inflammatory Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 28, 2014